National Institute of Allergy and Infectious Diseases, National Institutes of Health - May 17, 2006

Globally, through the end of 2005, approximately 25 million people had died and 40 million people were living with HIV/AIDS, including more than 8 million individuals residing in Asia. According to the U.S. Centers for Disease Control and Prevention, the number of people with AIDS in the United States continues to rise among Asians and Pacific Islanders. From 1993 through 2004, the number of Asians and Pacific Islanders living with AIDS increased more than threefold, to 4,045. Most experts speculate that the true number of Asians and Pacific Islanders with AIDS may actually be higher due to underreporting and misclassification of cases in API communities. These statistics and trends reflect a growing health concern for Asians and Pacific Islanders, who are one of the fastest-growing racial/ethnic populations in the United States as well as an emerging group at high risk for HIV/AIDS

Public health officials face a number of formidable barriers in their efforts to raise awareness of HIV/AIDS and promote prevention activities within API communities. The most significant challenge is the sheer magnitude and diversity of API nationalities and cultures, which encompass more than 100 languages and dialects. These language and cultural differences can directly and indirectly affect access and use of medical care. This is especially true for many recent immigrants who are not familiar with the U.S. health care system. In addition, a limited number of trained health care providers understand API traditions and culture in relation to medical care and preferences. Efforts to overcome these obstacles require linguistically and culturally tailored messages and greater awareness from the public health community in planning and implementing HIV/AIDS outreach and educational programs and strategies within the API communities.

The National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health, is committed to a comprehensive strategy to controlling HIV/AIDS that includes a robust biomedical research program to develop new prevention and treatment measures. Currently, more than two dozen antiretroviral drugs and drug combinations have been approved by the Food and Drug Administration to treat individuals infected with HIV. However, these drugs do not cure HIV infection or AIDS. They can suppress the virus, even to virtually undetectable levels, but are unable to completely eliminate HIV from the body and do not prevent an HIV-infected person from passing the virus on to others.

The persistence of HIV infection highlights a compelling need for a preventive vaccine and other prophylactic measures. Despite significant progress and the efforts of many scientists around the world, a safe and effective HIV vaccine does not exist. NIAID remains firmly committed to developing and testing effective HIV vaccines, as well as topical microbicides that women could use to protect themselves from HIV and other sexually transmitted pathogens. Currently, more than 30 candidate vaccines are being tested worldwide. But to determine whether an HIV vaccine or prevention strategy works in all populations, they must be tested in all populations. Therefore, it is critical that Asians and Pacific Islanders participate in HIV/AIDS clinical research, either by volunteering for a trial, or supporting the involvement of others in such trials. We need the support of the API communities to continue our fight against HIV/AIDS.

For this 2nd annual National Asian and Pacific Islander HIV/AIDS Awareness Day, I encourage you to join the effort to educate and raise awareness of HIV/AIDS in API communities. Only by working together can we remove barriers to prevention and treatment, save lives and prevent the further spread of HIV.

Dr. Fauci is director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health in Bethesda, Maryland.

###

Media inquiries can be directed to the NIAID News Office at 301-402-1663, niaidnews@niaid.nih.gov.
060517
NI060502

Published 2006 - National Institute of Allergy and Infectious Diseases . All material contained in this report is in the public domain and may be used and reprinted without special permission; citation to source, however, is appreciated.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, the Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.

Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .